Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

Radicle Science has pioneered a remarkable ability to put non-pharmaceutical products through large, rigorous clinical trials, thereby unlocking powerful new possibilities for affordable treatments.

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD ...

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

The right balance between the seriousness of the disease and the excitement over advances in treatment makes this interactive, immersive experience memorable ...

Peter WT Pisters, M.D., president of The University of Texas MD Anderson Cancer Center, was honored today with the Charles M.

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center ...

Post-diagnosis weight gain over ~1.5 years is consistently associated with increased breast cancer–specific and all-cause mortality across meta-analyses. How GLP-1 weight-loss drugs fit after breast ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

The evolving story of GLP-1 receptor agonists in oncology has yet another new chapter.Several studies presented at San Antonio Breast Cancer Symposium suggested the medications may help extend ...

How can I deliver care not just to the 100,000 patients who might have cancer but to the 500,000 patients who may be at risk of cancer?” That question is shaping the early tenure of Anirban Maitra, MD ...

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.